Now that vaccinated women have entered the screening population, we are seeing HPV 16 and 18 decreasing. These changes in HPV genotype prevalence may have a significant impact on the clinical management of cervical cancer, and an HPV test with extended genotyping may change the way we screen for cervical cancer as well. Joining Dr. Matt Birnholz to discuss the role of HPV extended genotyping in cervical cancer screening and the importance of identifying HPV 31 is Dr. Mark Stoler, Professor of Pathology and Clinical Gynecology at the University of Virginia Health System.